Literature DB >> 15218297

Estimating the probability of cancer with several tumor markers in patients with colorectal disease.

Monika Carpelan-Holmström1, Johanna Louhimo, Ulf-Håkan Stenman, Henrik Alfthan, Heikki Järvinen, Caj Haglund.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate and compare serum tumor markers, carcinoembryonic antigen (CEA), CA 19-9, CA 242, CA 72-4 and hCGbeta, and their value in the diagnosis of malignant colorectal disease.
METHODS: The serum concentrations of the markers were measured in 204 patients with colorectal cancer and in 104 inpatients with benign colorectal disease. The combined use of the markers was evaluated with a logistic regression analysis.
RESULTS: When all five markers were evaluated in the same model, only CEA and CA 72-4 provided significant diagnostic information (p < 0.001), indicating that their combination improves the accuracy. The probability of cancer for each patient was calculated entering CEA and CA 72-4 in the logistic regression model. Receiver-operating characteristic curves were constructed, and the difference in the area under the curve (AUC) values was determined between the markers and the calculated probability of cancer. Of the individual markers, the highest AUC was observed for CEA (AUC = 0.746). The difference in the AUC between CEA and CA 72-4 (AUC = 0.716) was insignificant (p = 0.492), but between CEA and the other three markers it was significant (p < 0.015). The calculated probability of cancer index, based on a combination of CEA and CA 72-4, had a significantly higher AUC (AUC = 0.804) than CEA alone (AUC = 0.746; p = 0.046).
CONCLUSIONS: The diagnostic value of CA 72-4 was additive to that of CEA in colorectal cancer, and both markers contributed with significant diagnostic information. As a diagnostic test, the probability of cancer calculated with logistic regression provided higher accuracy than any of the markers alone, implying that it might be a useful diagnostic tool. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15218297     DOI: 10.1159/000078330

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  9 in total

Review 1.  Screening for colorectal cancer: established and emerging modalities.

Authors:  Nikhil Pawa; Tan Arulampalam; John D Norton
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-01       Impact factor: 46.802

2.  Review of fluorescence guided surgery visualization and overlay techniques.

Authors:  Jonathan T Elliott; Alisha V Dsouza; Scott C Davis; Jonathan D Olson; Keith D Paulsen; David W Roberts; Brian W Pogue
Journal:  Biomed Opt Express       Date:  2015-09-03       Impact factor: 3.732

3.  Programmable probiotics for detection of cancer in urine.

Authors:  Tal Danino; Arthur Prindle; Gabriel A Kwong; Matthew Skalak; Howard Li; Kaitlin Allen; Jeff Hasty; Sangeeta N Bhatia
Journal:  Sci Transl Med       Date:  2015-05-27       Impact factor: 17.956

4.  The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer.

Authors:  M Cavia-Saiz; P Muñiz Rodríguez; B Llorente Ayala; M García-González; M J Coma-Del Corral; C García Girón
Journal:  Mol Biol Rep       Date:  2014-01-17       Impact factor: 2.316

Review 5.  Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer.

Authors:  Myron Arlen; Philip Arlen; Gene Coppa; Jim Crawford; XuePing Wang; Olga Saric; Alex Dubeykovskiy; Ernesto Molmenti
Journal:  World J Gastrointest Oncol       Date:  2014-06-15

6.  Multivariate explanatory model for sporadic carcinoma of the colon in Dukes' stages I and IIa.

Authors:  J M Villadiego-Sánchez; M Ortega-Calvo; R Pino-Mejías; A Cayuela; P Iglesias-Bonilla; F García-de la Corte; J M Santos-Lozano; José Lapetra-Peralta
Journal:  Int J Med Sci       Date:  2009-01-30       Impact factor: 3.738

Review 7.  Aberrant glycosylation as biomarker for cancer: focus on CD43.

Authors:  Franca Maria Tuccillo; Annamaria de Laurentiis; Camillo Palmieri; Giuseppe Fiume; Patrizia Bonelli; Antonella Borrelli; Pierfrancesco Tassone; Iris Scala; Franco Maria Buonaguro; Ileana Quinto; Giuseppe Scala
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

8.  Diagnostic Value of Serum Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) in Colorectal Cancer.

Authors:  Bo Qiu; Ling-Yu Chu; Xin-Xin Li; Yu-Hui Peng; Yi-Wei Xu; Jian-Jun Xie; Xiao-Yang Chen
Journal:  Onco Targets Ther       Date:  2020-11-24       Impact factor: 4.147

9.  Comparison of the clinicopathological features and prognoses of patients with schistosomal and nonschistosomal colorectal cancer.

Authors:  Zijian Wang; Zhixiang Du; Yinhua Liu; Wenjie Wang; Manman Liang; Aiping Zhang; Jianghua Yang
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.